For the year ending 2026-01-03, USNA had -$23,268K decrease in cash & cash equivalents over the period. $8,526K in free cash flow.
| Cash Flow | 2026-01-03 |
|---|---|
| Net earnings | 11,477 |
| Depreciation and amortization | 32,562 |
| Right-of-use asset reduction | 7,140 |
| (gain) loss on sale of property and equipment | 2,093 |
| Equity-based compensation expense | 13,828 |
| Deferred income taxes | -7,133 |
| Inventory write-down | 2,679 |
| Impairment | 6,967 |
| Inventories | 34,685 |
| Prepaid expenses and other assets | -621 |
| Accounts payable | 5,204 |
| Other liabilities | -14,218 |
| Net cash provided by (used in) operating activities | 22,349 |
| Proceeds from the settlement of net investment hedges | 0 |
| Payments for net investment hedge | 1,072 |
| Proceeds from acquisition working capital adjustment | 865 |
| Payments to acquire businesses, net of cash acquired | 0 |
| Proceeds from sale of property and equipment | 3,905 |
| Purchases of property and equipment | 13,823 |
| Net cash provided by (used in) investing activities | -10,125 |
| Repurchase of common stock | 27,507 |
| Borrowings on line of credit | 17,600 |
| Payments on line of credit | 26,600 |
| Payments related to tax withholding for net-share settled equity awards | 2,347 |
| Distributions to redeemable noncontrolling interest | 1,749 |
| Payments for contingent consideration | 0 |
| Net cash provided by (used in) financing activities | -40,603 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 5,111 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | -23,268 |
| Cash, cash equivalents, and restricted cash at beginning of period | 184,508 |
| Cash, cash equivalents, and restricted cash at end of period | 161,240 |
USANA HEALTH SCIENCES INC (USNA)
USANA HEALTH SCIENCES INC (USNA)